Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Regen BioPharma (RGBP) over the last 10 years, with Q4 2025 value amounting to $8850.0.

  • Regen BioPharma's Amortization of Deferred Charges fell 2997.86% to $8850.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $48359.0, marking a year-over-year increase of 33332.53%. This contributed to the annual value of $52148.0 for FY2025, which is 27983.31% up from last year.
  • According to the latest figures from Q4 2025, Regen BioPharma's Amortization of Deferred Charges is $8850.0, which was down 2997.86% from $34234.0 recorded in Q3 2025.
  • Over the past 5 years, Regen BioPharma's Amortization of Deferred Charges peaked at $34234.0 during Q3 2025, and registered a low of -$42043.0 during Q3 2024.
  • Over the past 5 years, Regen BioPharma's median Amortization of Deferred Charges value was $4436.0 (recorded in 2022), while the average stood at $6954.6.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 526304.35% in 2022, then plummeted by 496608.8% in 2024.
  • Regen BioPharma's Amortization of Deferred Charges (Quarter) stood at $22451.0 in 2021, then tumbled by 80.24% to $4436.0 in 2022, then fell by 1.56% to $4367.0 in 2023, then soared by 189.42% to $12639.0 in 2024, then decreased by 29.98% to $8850.0 in 2025.
  • Its Amortization of Deferred Charges stands at $8850.0 for Q4 2025, versus $34234.0 for Q3 2025 and -$7364.0 for Q2 2025.